Author

Richard Shames 1

1 PROTAGONIST THERAPEUTICS, Milpitas, United States of America

PTG-100, AN ORAL GUT-RESTRICTED PEPTIDE α4β7 ANTAGONIST, INDUCES CLINICAL AND HISTOLOGIC REMISSION IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS

William Sandborn, Brian Bressler, Scott D. Lee, Raj Bhandari, Bittoo Kanwar, Lucio Tozzi, Richard Shames, Geert R. D'Haens, Jean-Frederic Colombel, Stefan Schreiber, Silvio Danese, Rish K. Pai, Brian G. Feagan

SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL ORAL PEPTIDE THERAPEUTIC PTG-100 (alpha4-beta7 INTEGRIN ANTAGONIST) IN NORMAL HEALTHY VOLUNTEERS

Richard Shames

SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL ORAL PEPTIDE THERAPEUTIC PTG-100 (ALPHA4-BETA7 INTEGRIN ANTAGONIST) IN NORMAL HEALTHY VOLUNTEERS

Richard Shames, Lucio Tozzi, Larry Mattheakis, THAMIL ANNAMALAI, ASHOK BHANDARI, David Liu

Item 1 - 3 / 3
1